Theracryf Plc Share Price

EVG

GB00BSVYN304

Biotechnology & Medical Research

Market Closed - London S.E. 10:05:17 05/11/2026 pm IST			5-day change	1st Jan Change
0.1700 ^GBX	0.00%		-2.86%	-15.00%

31/10	Theracryf Plc - Special Call
20/10	Cora Gold shareholder Eagle Eye restructures holding	AN

Last Transcript: Theracryf Plc

Theracryf Plc - Special Call

31/10

More transcripts

Managers and Directors: Theracryf Plc

Manager	Title	Age	Since
Huw Jones CEO	Chief Executive Officer	64	01/10/2020
Toni Haenninen DFI	Director of Finance/CFO	-	05/09/2023
Glen Clack CTO	Chief Tech/Sci/R&D Officer	-	01/05/2021

Director	Title	Age	Since
Alan Barge BRD	Director/Board Member	-	14/10/2015
Huw Jones BRD	Director/Board Member	64	01/10/2020
Toni Haenninen BRD	Director/Board Member	-	01/01/2024

More insiders

TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
05/26/05	GBX 0.1700	0.00%	3,25,739
04/26/04	GBX 0.1700	0.00%	56,281
03/26/03	GBX 0.1700	0.00%	6,261
02/26/02	GBX 0.1700	0.00%	60,869
30/26/30	GBX 0.1700	-2.86%	63,82,997

Delayed Quote London S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.002290USD

Average target price

0.0159USD

Spread / Average Target

+593.83%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Theracryf Plc

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Theracryf Plc

Company calendar

Market Cap	62.57L 55.76L 51L 46.45L 87.55L 59Cr 89.91L 6.13Cr 2.45Cr 31Cr 2.35Cr 2.3Cr 99Cr	P/E 2027 *	-1.92x	P/E 2028 *	-2.16x
Enterprise Value	61.89L 55.15L 50.44L 45.94L 86.59L 58Cr 88.92L 6.06Cr 2.42Cr 31Cr 2.32Cr 2.27Cr 98Cr	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	50.34%	Yield 2027 *	-	Yield 2028 *	-

31/10	Theracryf Plc - Special Call
20/10	Cora Gold shareholder Eagle Eye restructures holding	AN
19/10	TheraCryf Completes Preclinical Safety Studies for Orexin-1 Addiction Drug Candidate	MT
03/10	Tooru gluten-free brand secures news listing	AN
29/09	Theracryf Plc Auditor Raises 'Going Concern' Doubt	CI
28/09	Theracryf Plc, 2026 Earnings Call, Sep 28, 2026
28/09	EARNINGS: US Solar Fund eyes "modest" fourth-quarter dividend	AN
28/09	Theracryf Plc Reports Earnings Results for the Full Year Ended March 31, 2026	CI
21/08	Theracryf's fund raise; Potter & Moore sales struggle	AN
14/05	EARNINGS & TRADING: Nexus Infrastructure first-half loss narrows	AN
14/05	Shares up as Strait of Hormuz talks lift mood	AN
14/05	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down	AN
27/04	Theracryf Plc - Shareholder/Analyst Call

14/05	Theracryf : Turner Pope Investments – Top-line Toxicology Data	PU
22/04	Theracryf : Turner Pope Investments – TheraCryf plc Research Note	PU
14/04	Theracryf : Turner Pope Investments – indicative proposal for Ox-1 / DAT programmes	PU
14/04	Theracryf : Capital Access Group – Ox-1/DAT programmes – indicative proposal	PU
13/04	Theracryf : Capital Access Group – Orexin M&A demonstrates industry appetite	PU

1 week	-2.86%
1 month	-5.56%
3 months	-15.00%
6 months	-22.73%
Current year	-15.00%

1 week	0.16	0.18
1 month	0.16	0.19
Current year	0.16	0.27
1 year	0.16	0.27
3 years	0.16	2
5 years	0.16	7.8
10 years	0.16	30.25

Theracryf Plc Share Price

Stocks

EVG

GB00BSVYN304

Biotechnology & Medical Research

Valuation: Theracryf Plc

Chart: Theracryf Plc

Latest news: Theracryf Plc

Last Transcript: Theracryf Plc

Press Releases: Theracryf Plc

Quotes and Performance

Price Extremes

Managers and Directors: Theracryf Plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/10/25	Tracarta Ltd.	Buy	Company	73,42,296	0.3448%
22/05/25	Edward Wardle	Others	Director	42,27,27,272	19.8499%
04/03/25	Helen Kuhlman	Buy	Chief Operating Officer	15,00,000	0.2945%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERACRYF PLC	0.00%	-2.86%	-	-	62.55L
Average	0.00%
Weighted average by Cap.	0.00%

	2027 *	2028 *
Net sales	-	-
Net income	-29.55L -26.33L -24.09L -21.94L -41.35L -28Cr -42.46L -2.89Cr -1.16Cr -15Cr -1.11Cr -1.09Cr -47Cr	-29.55L -26.33L -24.09L -21.94L -41.35L -28Cr -42.46L -2.89Cr -1.16Cr -15Cr -1.11Cr -1.09Cr -47Cr
Net Debt	-68.93T -61.42T -56.18T -51.17T -96.45T -65.14L -99.05T -7L -3L -34.5L -3L -3L -1.09Cr	30.2L 26.91L 24.61L 22.42L 42.25L 29Cr 43.39L 2.96Cr 1.18Cr 15Cr 1.13Cr 1.11Cr 48Cr

Markets		Quality
London S.E.	EVG	Delayed
Deutsche Boerse AG	8EV	Delayed